Neovacs : secures €5 million, from the public funding program "Investments for the Future" to support clinical and industrial development for the therapeutic vaccine INFalpha-Kinoïd

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE

Neovacs secures €5 million, from the public funding program "Investments for the Future"
 to support clinical and industrial development for the therapeutic vaccine INFalpha-Kinoïd

Paris and Boston, January 6^th 2016 - NEOVACS (Alternext Paris: ALNEV), has concluded an agreement which provides non-dilutive funding of five million euros for over the next four years, in the form of grants and repayable advances. 

This funding decision made by The General Commission for Investment and operated by Bpifrance^[1]:
#_ftn1, is part of the program: "PIAVE - Industrial project for the future" and will be used to finalize clinical development and to initiate the industrialization process for the therapeutic vaccine IFN-Kinoïd.

Miguel Sieler, CEO of Neovacs said: "We are proud that the development of our IFN-Kinoïd has been included in this French state plan, dedicated to the most promising industrial projects. The support from the General Commission for Investment and Bpifrance, approved after an extensive study by different public institutions, confirms the value and credibility of our technology platform. This decision considers also the chances of success of this treatment for autoimmune diseases, specifically in Lupus, which affects more than five million patients around the world."

This project is based on the following elements:

• Considering the low quantities of vaccines required to treat each patient, manufacturing equipment and infrastructure will be of moderate size. Therefore, Investments and project schedule are compatible with the actual scope of the company.   
• Neovacs will be able to maintain control over the technology and the manufacturing process.
• Production costs will be under direct control.

In the first instance, Neovacs will scale up the production process from clinical batches to industrial scale.

The main investment expenses concerning the infrastructure and acquisition of equipment will begin right after the Phase IIb clinical trial with IFN-Kinoïd in Lupus, which is currently ongoing. The production site will be located close to Paris and should generate between 50 and 100 new high-qualified employees in the long term.

Neovacs wants to be operational at the time of submission to health authorities for registration around 2020 and to supply in the future all licensing partners in their respective markets.

At the end of 2015, Neovacs signed a licensing agreement with CKD Pharmaceuticals in South Korea. During this new investment stage, Neovacs will continue to use the current clinical batch manufacturer for the South-Korean market and commercial sales by CKD from probably 2018.

Contacts

Corporate Communication & Investor Relations-NEOVACS
Charlène Masson
+33 (0)1 53 10 93 00
cmasson@neovacs.com:
mailto:cmasson@neovacs.com

Investor Relations / Financial Communications - NewCap
Valentine Brouchot / Pierre Laurent
+33 (0)1 44 71 94 94
neovacs@newcap.:
mailto:neovacs@newcap.eueu

Investor Relations / Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu:
mailto:raimund.gabriel@mc-services.eu

Press / U.S. Inquiries - The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com:
mailto:msollid@theruthgroup.com / jgreen@theruthgroup.com

Bpifrance - Media Relations
Vanessa Godet
+33 (0)1 41 79 84 33
Vanessa.godet@bpifrance.fr:
mailto:Vanessa.godet@bpifrance.fr